RNAi-Related Inhibition of TNF-alpha Signaling Pathway for Treatment of Ocular Angiogenesis

Abstract: RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition, such as ocular angiogenesis, retinal ischemia, and diabetic retinopathy.
Patent Number: US2016326533(A1)
Public Date:
Inventor: CHATTERTON JON E [US]; CLARK ABBOT F [US]; BINGAMAN DAVID P [US]; WAX MARTIN B [US]; TIMMERS ADRIAN
Applicant: ARROWHEAD PHARMACEUTICALS INC [US]
Application Number: US201615218180 20160725Global Dossier
Application Date:
Priority Number: US201615218180 20160725;US201514827418 20150817;US201414270197 20140505;US201113169549 20110627;US20100825552 20100629;US20080184351 20080801;US20070953825P 20070803
International Classification: C12N15/113
Cooperative Classification: C12N15/113; C12N15/1136; C12N15/1137; C12N15/1138; C12N2310/111; C12N2310/14; C12N2310/141; C12N2310
Assignee:
Nation: